Gilead Sciences has acquired Nimbus liver program for $1.2 billion. Both companies are looking forward to making advancements together and meet the needs of patients with nonalcoholic steatohepatitis.
Gilead Sciences Buys Nimbus Therapeutics' Liver Drug Program For $1.2 Billion
Tech Times - 5 Apr 2016 17:11
Gilead Sciences has acquired Nimbus liver program for $1.2 billion. Both companies are looking forward to making advancements together and meet the needs of patients with nonalcoholic steatohepatitis.
Share this Article
Recommended